Zevra Therapeutics Submits U.S. Patent For MIPLYFFA To FDA For Listing In Orange Book Publication; Patent Expires On November 19, 2041

MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041

Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that it has submitted U.S. Patent No. 11,707,456 for MIPLYFFA® (arimoclomol) to the U.S. Food and Drug Administration for listing in the publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The patent expires on November 19, 2041.